Company news

vTv Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

May 10, 2023

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 5, 2023

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

January 31, 2023

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

December 12, 2022

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

November 9, 2022

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

August 14, 2022

vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer

July 26, 2022

vTv Therapeutics Announces Investment by CinRx Pharma

July 24, 2022

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

June 3, 2022

vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare

May 31, 2022

vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update

May 11, 2022

vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 28, 2022

vTv Therapeutics Announces CEO Transition

March 2, 2022

vTv Therapeutics Shares Updated Corporate Presentation

January 12, 2022

vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations

December 5, 2021

vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update

November 8, 2021

vTv Therapeutics Announces Deepa Prasad as New President and CEO

October 19, 2021

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

October 11, 2021

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

September 22, 2021

vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update

August 3, 2021

vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737

June 28, 2021

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer

June 21, 2021

vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update

May 4, 2021

vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes

April 12, 2021

TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin

April 11, 2021

vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399

March 22, 2021

vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes

March 17, 2021

vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

March 7, 2021

vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

February 23, 2021

vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes

February 22, 2021

vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

February 16, 2021

vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually

January 5, 2021

vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes

December 14, 2020

vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio

December 14, 2020

vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital

November 23, 2020

vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update

November 4, 2020

vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study

November 3, 2020

vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event

October 28, 2020

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes

September 22, 2020

vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting

September 15, 2020

vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors

September 14, 2020

vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update

August 2, 2020

vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference

July 26, 2020

vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients

June 12, 2020

vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format

May 21, 2020

vTv Therapeutics Announces 2020 First Quarter Financial Results and Update

May 6, 2020

vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

February 19, 2020

vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

February 9, 2020

vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

February 6, 2020

vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update

October 29, 2019

← Newer news releases · Older news releases →

Decks

The 5 newest of 18 decks. Every deck is listed under its year.